ID   PGM2L_HUMAN             Reviewed;         622 AA.
AC   Q6PCE3; Q96MQ7; Q9UIK3;
DT   19-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 3.
DT   28-JUN-2023, entry version 158.
DE   RecName: Full=Glucose 1,6-bisphosphate synthase {ECO:0000305|PubMed:17804405};
DE            EC=2.7.1.106 {ECO:0000269|PubMed:17804405};
DE   AltName: Full=PMMLP;
DE   AltName: Full=Phosphoglucomutase-2-like 1;
GN   Name=PGM2L1 {ECO:0000312|HGNC:HGNC:20898}; Synonyms=BM32A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Mori K., Miyoshi Y., Nakamura Y.;
RL   Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-531.
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS PRO-14 AND ILE-531.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=17804405; DOI=10.1074/jbc.m706818200;
RA   Maliekal P., Sokolova T., Vertommen D., Veiga-da-Cunha M.,
RA   Van Schaftingen E.;
RT   "Molecular identification of mammalian phosphopentomutase and glucose-1,6-
RT   bisphosphate synthase, two members of the alpha-D-phosphohexomutase
RT   family.";
RL   J. Biol. Chem. 282:31844-31851(2007).
RN   [6]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=18927083; DOI=10.1074/jbc.m805224200;
RA   Veiga-da-Cunha M., Vleugels W., Maliekal P., Matthijs G.,
RA   Van Schaftingen E.;
RT   "Mammalian phosphomannomutase PMM1 is the brain IMP-sensitive glucose-1,6-
RT   bisphosphatase.";
RL   J. Biol. Chem. 283:33988-33993(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-175, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-175, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-175, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-175, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   INVOLVEMENT IN NEDHFS, VARIANTS NEDHFS 58-ARG--VAL-622 DEL AND
RP   428-GLU--VAL-622 DEL, AND FUNCTION.
RX   PubMed=33979636; DOI=10.1016/j.ajhg.2021.04.017;
RA   Morava E., Schatz U.A., Torring P.M., Abbott M.A., Baumann M.,
RA   Brasch-Andersen C., Chevalier N., Dunkhase-Heinl U., Fleger M., Haack T.B.,
RA   Nelson S., Potelle S., Radenkovic S., Bommer G.T., Van Schaftingen E.,
RA   Veiga-da-Cunha M.;
RT   "Impaired glucose-1,6-biphosphate production due to bi-allelic PGM2L1
RT   mutations is associated with a neurodevelopmental disorder.";
RL   Am. J. Hum. Genet. 108:1151-1160(2021).
CC   -!- FUNCTION: Glucose 1,6-bisphosphate synthase using 1,3-
CC       bisphosphoglycerate as a phosphate donor and a series of 1-phosphate
CC       sugars, including glucose 1-phosphate, mannose 1-phosphate, ribose 1-
CC       phosphate and deoxyribose 1-phosphate, as acceptors (PubMed:17804405).
CC       In vitro, also exhibits very low phosphopentomutase and
CC       phosphoglucomutase activity which are most probably not physiologically
CC       relevant (PubMed:17804405). {ECO:0000269|PubMed:17804405,
CC       ECO:0000269|PubMed:18927083, ECO:0000269|PubMed:33979636}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(2R)-3-phospho-glyceroyl phosphate + alpha-D-glucose 1-
CC         phosphate = (2R)-3-phosphoglycerate + alpha-D-glucose 1,6-
CC         bisphosphate + H(+); Xref=Rhea:RHEA:16769, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:57604, ChEBI:CHEBI:58272, ChEBI:CHEBI:58392,
CC         ChEBI:CHEBI:58601; EC=2.7.1.106;
CC         Evidence={ECO:0000269|PubMed:17804405, ECO:0000269|PubMed:18927083};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:16770;
CC         Evidence={ECO:0000269|PubMed:18927083};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(2R)-3-phospho-glyceroyl phosphate + alpha-D-glucose 6-
CC         phosphate = (2R)-3-phosphoglycerate + alpha-D-glucose 1,6-
CC         bisphosphate + H(+); Xref=Rhea:RHEA:70911, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:57604, ChEBI:CHEBI:58225, ChEBI:CHEBI:58272,
CC         ChEBI:CHEBI:58392; Evidence={ECO:0000269|PubMed:17804405};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70912;
CC         Evidence={ECO:0000305|PubMed:17804405};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(2R)-3-phospho-glyceroyl phosphate + alpha-D-ribose 1-
CC         phosphate = (2R)-3-phosphoglycerate + alpha-D-ribose 1,5-bisphosphate
CC         + H(+); Xref=Rhea:RHEA:70899, ChEBI:CHEBI:15378, ChEBI:CHEBI:57604,
CC         ChEBI:CHEBI:57720, ChEBI:CHEBI:58272, ChEBI:CHEBI:68688;
CC         Evidence={ECO:0000269|PubMed:17804405};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70900;
CC         Evidence={ECO:0000305|PubMed:17804405};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(2R)-3-phospho-glyceroyl phosphate + 2-deoxy-alpha-D-ribose 1-
CC         phosphate = (2R)-3-phosphoglycerate + 2-deoxy-alpha-D-ribose 1,5-
CC         bisphosphate + H(+); Xref=Rhea:RHEA:70903, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:57259, ChEBI:CHEBI:57604, ChEBI:CHEBI:58272,
CC         ChEBI:CHEBI:190126; Evidence={ECO:0000269|PubMed:17804405};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70904;
CC         Evidence={ECO:0000305|PubMed:17804405};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(2R)-3-phospho-glyceroyl phosphate + alpha-D-mannose 1-
CC         phosphate = (2R)-3-phosphoglycerate + alpha-D-mannose 1,6-
CC         bisphosphate + H(+); Xref=Rhea:RHEA:70907, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:57604, ChEBI:CHEBI:58272, ChEBI:CHEBI:58409,
CC         ChEBI:CHEBI:190127; Evidence={ECO:0000269|PubMed:17804405};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70908;
CC         Evidence={ECO:0000305|PubMed:17804405};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.32 mM for alpha-D-glucose 1-phosphate (for glucose
CC         1,6-bisphosphate synthase activity) {ECO:0000269|PubMed:17804405};
CC         KM=0.44 mM for alpha-D-ribose 1-phosphate (for aldose-bisphosphate
CC         synthase activity) {ECO:0000269|PubMed:17804405};
CC         KM=0.3 mM for 2-deoxyribose 1-phosphate (for aldose-bisphosphate
CC         synthase activity) {ECO:0000269|PubMed:17804405};
CC         KM=0.79 mM for alpha-D-mannose 1-phosphate (for aldose-bisphosphate
CC         synthase activity) {ECO:0000269|PubMed:17804405};
CC         KM=0.36 mM for alpha-D-glucose 6-phosphate (for aldose-bisphosphate
CC         synthase activity) {ECO:0000269|PubMed:17804405};
CC         Vmax=1.45 umol/min/mg enzyme for alpha-D-glucose 1-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC         Vmax=1.93 umol/min/mg enzyme for alpha-D-ribose 1-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC         Vmax=1.36 umol/min/mg enzyme for 2-deoxyribose 1-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC         Vmax=1.38 umol/min/mg enzyme for alpha-D-mannose 1-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC         Vmax=0.77 umol/min/mg enzyme for alpha-D-glucose 6-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC         Vmax=0.14 umol/min/mg enzyme for alpha-D-Ribose 5-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC         Vmax=0.04 umol/min/mg enzyme for 2-deoxyribose 5-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000305|PubMed:17804405}.
CC   -!- DISEASE: Neurodevelopmental disorder with hypotonia, dysmorphic facies,
CC       and skin abnormalities (NEDHFS) [MIM:620191]: An autosomal recessive
CC       neurodevelopmental disorder characterized by severe developmental and
CC       speech delay, dysmorphic facial features, ear anomalies, high arched
CC       palate, strabismus, hypotonia, and keratosis pilaris. Early obesity and
CC       seizures may be present in affected individuals.
CC       {ECO:0000269|PubMed:33979636}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the phosphohexose mutase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB019210; BAA82756.1; -; mRNA.
DR   EMBL; AK056591; BAB71227.1; -; mRNA.
DR   EMBL; AP001085; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC059360; AAH59360.1; -; mRNA.
DR   CCDS; CCDS8231.1; -.
DR   RefSeq; NP_775853.2; NM_173582.4.
DR   AlphaFoldDB; Q6PCE3; -.
DR   SMR; Q6PCE3; -.
DR   BioGRID; 129496; 22.
DR   IntAct; Q6PCE3; 7.
DR   MINT; Q6PCE3; -.
DR   STRING; 9606.ENSP00000298198; -.
DR   iPTMnet; Q6PCE3; -.
DR   PhosphoSitePlus; Q6PCE3; -.
DR   BioMuta; PGM2L1; -.
DR   DMDM; 317373530; -.
DR   EPD; Q6PCE3; -.
DR   jPOST; Q6PCE3; -.
DR   MassIVE; Q6PCE3; -.
DR   MaxQB; Q6PCE3; -.
DR   PaxDb; Q6PCE3; -.
DR   PeptideAtlas; Q6PCE3; -.
DR   ProteomicsDB; 67064; -.
DR   Antibodypedia; 31067; 160 antibodies from 20 providers.
DR   DNASU; 283209; -.
DR   Ensembl; ENST00000298198.5; ENSP00000298198.4; ENSG00000165434.8.
DR   GeneID; 283209; -.
DR   KEGG; hsa:283209; -.
DR   MANE-Select; ENST00000298198.5; ENSP00000298198.4; NM_173582.6; NP_775853.2.
DR   UCSC; uc001ovb.2; human.
DR   AGR; HGNC:20898; -.
DR   CTD; 283209; -.
DR   GeneCards; PGM2L1; -.
DR   HGNC; HGNC:20898; PGM2L1.
DR   HPA; ENSG00000165434; Tissue enhanced (brain).
DR   MIM; 611610; gene.
DR   MIM; 620191; phenotype.
DR   neXtProt; NX_Q6PCE3; -.
DR   OpenTargets; ENSG00000165434; -.
DR   PharmGKB; PA134938366; -.
DR   VEuPathDB; HostDB:ENSG00000165434; -.
DR   eggNOG; KOG1220; Eukaryota.
DR   GeneTree; ENSGT00940000158353; -.
DR   HOGENOM; CLU_016950_0_1_1; -.
DR   InParanoid; Q6PCE3; -.
DR   OMA; PQDNGYK; -.
DR   OrthoDB; 1482at2759; -.
DR   PhylomeDB; Q6PCE3; -.
DR   TreeFam; TF300692; -.
DR   PathwayCommons; Q6PCE3; -.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   SABIO-RK; Q6PCE3; -.
DR   SignaLink; Q6PCE3; -.
DR   BioGRID-ORCS; 283209; 17 hits in 1159 CRISPR screens.
DR   ChiTaRS; PGM2L1; human.
DR   GenomeRNAi; 283209; -.
DR   Pharos; Q6PCE3; Tbio.
DR   PRO; PR:Q6PCE3; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q6PCE3; protein.
DR   Bgee; ENSG00000165434; Expressed in middle temporal gyrus and 186 other tissues.
DR   Genevisible; Q6PCE3; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0047933; F:glucose-1,6-bisphosphate synthase activity; IDA:UniProtKB.
DR   GO; GO:0016868; F:intramolecular transferase activity, phosphotransferases; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW.
DR   CDD; cd05799; PGM2; 1.
DR   Gene3D; 3.40.120.10; Alpha-D-Glucose-1,6-Bisphosphate, subunit A, domain 3; 3.
DR   InterPro; IPR005844; A-D-PHexomutase_a/b/a-I.
DR   InterPro; IPR016055; A-D-PHexomutase_a/b/a-I/II/III.
DR   InterPro; IPR005845; A-D-PHexomutase_a/b/a-II.
DR   InterPro; IPR005846; A-D-PHexomutase_a/b/a-III.
DR   InterPro; IPR005843; A-D-PHexomutase_C.
DR   InterPro; IPR036900; A-D-PHexomutase_C_sf.
DR   PANTHER; PTHR45745:SF2; GLUCOSE 1,6-BISPHOSPHATE SYNTHASE; 1.
DR   PANTHER; PTHR45745; PHOSPHOMANNOMUTASE 45A; 1.
DR   Pfam; PF02878; PGM_PMM_I; 1.
DR   Pfam; PF02879; PGM_PMM_II; 1.
DR   Pfam; PF02880; PGM_PMM_III; 1.
DR   Pfam; PF00408; PGM_PMM_IV; 1.
DR   SUPFAM; SSF55957; Phosphoglucomutase, C-terminal domain; 1.
DR   SUPFAM; SSF53738; Phosphoglucomutase, first 3 domains; 3.
PE   1: Evidence at protein level;
KW   Carbohydrate metabolism; Cytoplasm; Disease variant; Glucose metabolism;
KW   Intellectual disability; Isomerase; Magnesium; Metal-binding;
KW   Phosphoprotein; Reference proteome; Transferase.
FT   CHAIN           1..622
FT                   /note="Glucose 1,6-bisphosphate synthase"
FT                   /id="PRO_0000147784"
FT   ACT_SITE        175
FT                   /note="Phosphoserine intermediate"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   BINDING         73
FT                   /ligand="alpha-D-glucose 1,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58392"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   BINDING         175
FT                   /ligand="alpha-D-glucose 1,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58392"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   BINDING         175
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /note="via phosphate group"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   BINDING         332
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   BINDING         334
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   BINDING         336
FT                   /ligand="alpha-D-glucose 1,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58392"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   BINDING         337
FT                   /ligand="alpha-D-glucose 1,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58392"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   BINDING         434
FT                   /ligand="alpha-D-glucose 1,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58392"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   BINDING         436
FT                   /ligand="alpha-D-glucose 1,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58392"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   BINDING         448
FT                   /ligand="alpha-D-glucose 1,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:58392"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   MOD_RES         175
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   VARIANT         14
FT                   /note="L -> P (in dbSNP:rs12049823)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_028094"
FT   VARIANT         58..622
FT                   /note="Missing (in NEDHFS)"
FT                   /evidence="ECO:0000269|PubMed:33979636"
FT                   /id="VAR_087994"
FT   VARIANT         428..622
FT                   /note="Missing (in NEDHFS)"
FT                   /evidence="ECO:0000269|PubMed:33979636"
FT                   /id="VAR_087995"
FT   VARIANT         531
FT                   /note="V -> I (in dbSNP:rs592644)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334"
FT                   /id="VAR_028095"
FT   VARIANT         608
FT                   /note="N -> I (in dbSNP:rs36014178)"
FT                   /id="VAR_056665"
FT   CONFLICT        69
FT                   /note="T -> A (in Ref. 2; BAB71227)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   622 AA;  70442 MW;  8AE00403B5D973CA CRC64;
     MAENTEGDLN SNLLHAPYHT GDPQLDTAIG QWLRWDKNPK TKEQIENLLR NGMNKELRDR
     LCCRMTFGTA GLRSAMGAGF CYINDLTVIQ STQGMYKYLE RCFSDFKQRG FVVGYDTRGQ
     VTSSCSSQRL AKLTAAVLLA KDVPVYLFSR YVPTPFVPYA VQKLKAVAGV MITASHNRKE
     DNGYKVYWET GAQITSPHDK EILKCIEECV EPWNGSWNDN LVDTSPLKRD PLQDICRRYM
     EDLKKICFYR ELNSKTTLKF VHTSFHGVGH DYVQLAFKVF GFKPPIPVPE QKDPDPDFST
     VKCPNPEEGE SVLELSLRLA EKENARVVLA TDPDADRLAA AELQENGCWK VFTGNELAAL
     FGWWMFDCWK KNKSRNADVK NVYMLATTVS SKILKAIALK EGFHFEETLP GFKWIGSRII
     DLLENGKEVL FAFEESIGFL CGTSVLDKDG VSAAVVVAEM ASYLETMNIT LKQQLVKVYE
     KYGYHISKTS YFLCYEPPTI KSIFERLRNF DSPKEYPKFC GTFAILHVRD VTTGYDSSQP
     NKKSVLPVSK NSQMITFTFQ NGCVATLRTS GTEPKIKYYA EMCASPDQSD TALLEEELKK
     LIDALIENFL QPSKNGLIWR SV
//
